Skip to content


Infectious Diseases of Poverty

Open Access

The monetary value of human lives lost due to neglected tropical diseases in Africa

Infectious Diseases of Poverty20176:165

Received: 19 December 2016

Accepted: 29 November 2017

Published: 18 December 2017



Neglected tropical diseases (NTDs) are an important cause of death and disability in Africa. This study estimates the monetary value of human lives lost due to NTDs in the continent in 2015.


The lost output or human capital approach was used to evaluate the years of life lost due to premature deaths from NTDs among 10 high/upper-middle-income (Group 1), 17 middle-income (Group 2) and 27 low-income (Group 3) countries in Africa. The future losses were discounted to their present values at a 3% discount rate. The model was re-analysed using 5% and 10% discount rates to assess the impact on the estimated total value of human lives lost.


The estimated value of 67 860 human lives lost in 2015 due to NTDs was Int$ 5 112 472 607. Out of that, 14.6% was borne by Group 1, 57.7% by Group 2 and 27.7% by Group 3 countries. The mean value of human life lost per NTD death was Int$ 231 278, Int$ 109 771 and Int$ 37 489 for Group 1, Group 2 and Group 3 countries, respectively. The estimated value of human lives lost in 2015 due to NTDs was equivalent to 0.1% of the cumulative gross domestic product of the 53 continental African countries.


Even though NTDs are not a major cause of death, they impact negatively on the productivity of those affected throughout their life-course. Thus, the case for investing in NTDs control should also be influenced by the value of NTD morbidity, availability of effective donated medicines, human rights arguments, and need to achieve the NTD-related target 3.3 of the United Nations Sustainable Development Goal 3 (on health) by 2030.


Neglected tropical diseasesNon-health gross domestic product lossValue of lifeLost output approachHuman capital approachAfrica

Multilingual abstracts

Please see Additional file 1 for translations of the abstract into the five official working languages of the United Nations.


Africa has 54 countries: 1 (1.9%) high-income, 9 (16.7%) upper-middle-income, 17 (31.5%) lower-middle-income and 27 (50%) low-income countries (see Table 1) [1]. The continent had a population of approximately 1 184 500 000 people in 2015 [2]. The total gross domestic product (GDP) for Africa that year was approximately International Dollars (Int$) 6 045 831 000 000 in 2015 [3].
Table 1

World Bank analytical classifications

Economic classification

Gross national income per capita in US$ (the World Bank’s fiscal year – 1 July 2015 to 30 June 2016)


High-income economies

> 12 475

Seychelles (1)

Upper-middle-income economies

4 036–12 475

Algeria, Angola, Botswana, Equatorial Guinea, Gabon, Libya, Mauritius, Namibia, South Africa (9)

Lower-middle-income economies

1 026–4 035

Cape Verde, Cameroon, Republic of Congo, Cote d’Ivoire, Djibouti, Egypt, Ghana, Kenya, Lesotho, Mauritania, Morocco, Nigeria, Sao Tome and Principe, Sudan, Swaziland, Tunisia, Zambia (17)

Low-income economies

≤ 1 025

Benin, Burkina Faso, Burundi, Central African Republic, Chad, Comoros, DRC, Eritrea, Ethiopia, The Gambia, Guinea, Guinea-Bissau, Liberia, Madagascar, Malawi, Mali, Mozambique, Niger, Rwanda, Senegal, Sierra Leone, Somalia, South Sudan, Tanzania, Togo, Uganda, Zimbabwe (27)

Source: World Bank [1]

Globally, an estimated total of 56 228 951 deaths from all causes occurred in 2015. Approximately 10 522 529 of those deaths happened in the African continent. Of these, 5 497 996 (52.2%) were from communicable, maternal, perinatal and nutritional conditions; 3 985 251 (37.9%) were from non-communicable diseases; and 1 039 282 (9.9%) were from injuries [4].

Out of the total global number of deaths, 206 155 resulted from NTDs, of which 67 860 (32.9%) occurred in Africa [4].

According to various reports [513], NTDs afflict mainly the poorest people in Africa, often with devastating effects for their entire life-course. They erode patients’ intellectual capacities, school attendance and educational performance, labour productivity and income earning potential, and thus aggravate and perpetuate inter-generational poverty among societies living in endemic areas [513].

In 2015, the United Nations (UN) General Assembly adopted resolution A/69/L.85 on the 2030 agenda for sustainable development. It contains 17 Sustainable Development Goals (SDGs), of which SDG 3 is centred on ensuring healthy lives and promoting wellbeing for all. The SDG has 13 targets, of which target 3.3 reads: “By 2030, end the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases and combat hepatitis, water-borne diseases and other communicable diseases” (p. 16) [14]. There is therefore an urgent need for collating economic burden evidence to use in advocacy in African countries among the ministries of finance, the private sector and development partners to increase investment towards global efforts to achieve the abovementioned target on ending the NTD epidemic.

Globally, a number of studies have been conducted on the economic burden of a single NTD [1531] in one or a few countries [32, 33]. To date, no study has attempted to measure the value of human lives lost due to NTDs in all or the majority of countries in continental Africa. Therefore, the study reported in this paper was an attempt to contribute to bridging this knowledge gap.

The paper answers the question: What is the value of human lives lost due to NTDs in continental Africa? More specifically, the objective was to estimate the monetary value of human lives lost due to NTDs in Africa in 2015.


Study area and population

This study was conducted in the African continent, which has a total of 54 countries. Somalia was excluded from the study, as it did not have data on per-capita GDP and per-capita total health expenditure.

The study includes the following 16 NTDs as listed in the World Health Organization (WHO) Global Health Estimates 2015: African trypanosomiasis, schistosomiasis, leishmaniasis, lymphatic filariasis, cysticercosis, echinococcosis, dengue, rabies, ascariasis, leprosy, Chagas disease, trachoma, onchocerciasis, trichuriasis, hookworm disease and food-borne trematodes. There were no deaths reported in the WHO [4] source for the last six NTDs in African countries.

Study design: The lost output approach or human capital approach (HCA)

The late Professor Gavin Mooney [34] outlined three types of approaches used in deriving monetary values for human life: (a) the implied values (or revealed preferences) approach, which is based on values implied by past healthcare decisions; (b) the HCA or lost output approach, which equates the value of human life with the value of livelihood; and (c) the willingness-to-pay (or contingent valuation) approach, which is based on how much individuals are prepared to pay to reduce the risk of morbidity or death. The strengths and weaknesses of each approach have been exhaustively discussed in Linnerooth [35], Mooney [36] and Jones-Lee [37].

The HCA or lost output approach was first applied by Petty [38]. However, its theoretical and practical underpinnings have been refined and enhanced by Fein [39], Mushkin and Collings [40], Weisbrod [41], and Landefeld and Seskin [42]. The approach has been widely applied in Asia-Pacific countries [4353], North America [5460] and Europe [6166]. It has been applied in Africa to estimate the economic burdens of cholera [67], malaria [68, 69], HIV/AIDS [70, 71] and diabetes mellitus [72]. The specific approach used in the current study is similar to that developed and applied in estimating the indirect costs of child mortality [73], Ebola virus disease [74], tuberculosis [75] and maternal mortality [76] in the African region.

The choice of the HCA or lost output approach to place monetary values on years of human lives lost due to NTDs was based on successful past applications in estimating indirect costs of a number of health conditions in the region [7376]; and availability of data on GDPs and total health expenditure per capita for all countries (except one) in Africa.

According to Mooney [34], this approach:

“suggests that a life’s value can be measured in terms of the future expected life-time earnings of the individual concerned, adjusted to allow for working life expectancy, participation rates in the labour force, and various other factors. The value of life or, more accurately in this context, of livelihood is then obtained by discounting these future earnings to their present value as is usual in public and private investment decisions. For this reason, economists term it the ‘human capital’ approach.” (p.7)

The GDP is a monetary measure of the market value of all final goods and services produced within a country in a specific period, e.g. yearly in our case [77, 78]. The NTD premature mortality impacts negatively on all the components of the GDP, including consumption expenditure, investment, government expenditure and net exports, i.e. exports less imports. We used per-capita GDP data to value the years of life lost (YLLs) to premature mortality from NTDs. The per-capita GDP is obtained by dividing the total GDP of a country by its population. The WHO [79] and Chisholm et al. [80] advise that when the focus of an economic burden of a disease study is on overall productivity losses, the quantity of interest should be the effect on the pooled output of remunerated and unremunerated labour as measured by non-health GDP.

The value of human lives lost (VHLLost) due to NTDs in Africa is equal to the sum of non-health GDP losses of the 53 countries. The VHLLostdue to NTD deaths (NTDDs) in a country is the sum of the potential non-health GDP lost due to NTDDs among people aged 0–4 years (VHLLost0 − 4), 5–14 years (VHLLost5 − 14), 15–29 years (VHLLost15 − 29), 30–49 years (VHLLost30 − 49), 50–59 years VHLLost50 − 59, 60–69 years (VHLLost60 − 69), and 70 years and above VHLLost≥70 [7376].

The VHLLostassociated with NTDDs among persons of a specific age group equals the total discounted YLLs per-capita non-health GDP in purchasing power parity (PPP) and the total NTDDs for the age group [73, 74, 76]. Each country’s discounted value of human lives loss associated with NTDDs was appraised using the eqs. (1) to (8), as shown below:
$$ VHLLost=\left(\begin{array}{l}{VHLLost}_{0-4}+{VHLLost}_{5-14}+{VHLLost}_{15-29}+\\ {}{VHLLost}_{30-49}+{VHLLost}_{50-59}+{VHLLost}_{60-69}+{VHLLost}_{\ge 70}\end{array}\right) $$
$$ {\displaystyle \begin{array}{l}{VHLLost}_{0-4}=\sum \limits_{i=1}^k\left\{\left[1/{\left(1+r\right)}^k\right]\right.\times \left[{NHGDPPC}_{Int\$}\right]\times \left.\left[{NTDD}_{0-4}\right]\right\}=\\ {}\kern2.16em \left\{\left[1/{\left(1+r\right)}^1\right]\right.\times \left[{NHGDPPC}_{Int\$}\right]\times \left.\left[{NTDD}_{0-4}\right]\right\}+\\ {}\kern2.16em \left\{\left[1/{\left(1+r\right)}^2\right]\right.\times \left[{NHGDPPC}_{Int\$}\right]\times \left.\left[{NTDD}_{0-4}\right]\right\}+\dots +\\ {}\kern2.16em \left\{\left[1/{\left(1+r\right)}^k\right]\right.\times \left[{NHGDPPC}_{Int\$}\right]\times \left.\left[{NTDD}_{0-4}\right]\right\}\;\end{array}} $$
$$ {\displaystyle \begin{array}{l}{VHLLost}_{5-14}=\sum \limits_{i=1}^k\left\{\left[1/{\left(1+r\right)}^k\right]\right.\times \left[{NHGDPPC}_{Int\$}\right]\times \left.\left[{NTDD}_{5-14}\right]\right\}=\\ {}\kern2.16em \left\{\left[1/{\left(1+r\right)}^1\right]\right.\times \left[{NHGDPPC}_{Int\$}\right]\times \left.\left[{NTDD}_{5-14}\right]\right\}+\\ {}\kern2.16em \left\{\left[1/{\left(1+r\right)}^2\right]\right.\times \left[{NHGDPPC}_{Int\$}\right]\times \left.\left[{NTDD}_{5-14}\right]\right\}+\dots +\\ {}\kern2.16em \left\{\left[1/{\left(1+r\right)}^k\right]\right.\times \left[{NHGDPPC}_{Int\$}\right]\times \left.\left[{NTDD}_{5-14}\right]\right\}\end{array}} $$
$$ {\displaystyle \begin{array}{l}{VHLLost}_{15-29}=\sum \limits_{i=1}^k\left\{\left[1/{\left(1+r\right)}^k\right]\right.\times \left[{NHGDPPC}_{Int\$}\right]\times \left.\left[{NTDD}_{15-29}\right]\right\}=\\ {}\kern2.16em \left\{\left[1/{\left(1+r\right)}^1\right]\right.\times \left[{NHGDPPC}_{Int\$}\right]\times \left.\left[{NTDD}_{15-29}\right]\right\}+\\ {}\kern2.16em \left\{\left[1/{\left(1+r\right)}^2\right]\right.\times \left[{NHGDPPC}_{Int\$}\right]\times \left.\left[{NTDD}_{15-29}\right]\right\}+\dots +\\ {}\kern2.16em \left\{\left[1/{\left(1+r\right)}^k\right]\right.\times \left[{NHGDPPC}_{Int\$}\right]\times \left.\left[{NTDD}_{15-29}\right]\right\}\end{array}} $$
$$ {\displaystyle \begin{array}{l}{VHLLost}_{30-49}=\sum \limits_{i=1}^k\left\{\left[1/{\left(1+r\right)}^k\right]\right.\times \left[{NHGDPPC}_{Int\$}\right]\times \left.\left[{NTDD}_{30-49}\right]\right\}=\\ {}\kern2.16em \left\{\left[1/{\left(1+r\right)}^1\right]\right.\times \left[{NHGDPPC}_{Int\$}\right]\times \left.\left[{NTDD}_{30-49}\right]\right\}+\\ {}\kern2.16em \left\{\left[1/{\left(1+r\right)}^2\right]\right.\times \left[{NHGDPPC}_{Int\$}\right]\times \left.\left[{NTDD}_{30-49}\right]\right\}+\dots +\\ {}\kern2.16em \left\{\left[1/{\left(1+r\right)}^k\right]\right.\times \left[{NHGDPPC}_{Int\$}\right]\times \left.\left[{NTDD}_{30-49}\right]\right\}\end{array}} $$
$$ {\displaystyle \begin{array}{l}{VHLLost}_{50-59}=\sum \limits_{i=1}^k\left\{\left[1/{\left(1+r\right)}^k\right]\right.\times \left[{NHGDPPC}_{Int\$}\right]\times \left.\left[{NTDD}_{50-59}\right]\right\}=\\ {}\kern2.16em \left\{\left[1/{\left(1+r\right)}^1\right]\right.\times \left[{NHGDPPC}_{Int\$}\right]\times \left.\left[{NTDD}_{50-59}\right]\right\}+\\ {}\kern2.16em \left\{\left[1/{\left(1+r\right)}^2\right]\right.\times \left[{NHGDPPC}_{Int\$}\right]\times \left.\left[{NTDD}_{50-59}\right]\right\}+\dots +\\ {}\kern2.16em \left\{\left[1/{\left(1+r\right)}^k\right]\right.\times \left[{NHGDPPC}_{Int\$}\right]\times \left.\left[{NTDD}_{50-59}\right]\right\}\end{array}} $$
$$ {\displaystyle \begin{array}{l}{VHLLost}_{60-69}=\sum \limits_{i=1}^k\left\{\left[1/{\left(1+r\right)}^k\right]\right.\times \left[{NHGDPPC}_{Int\$}\right]\times \left.\left[{NTDD}_{60-69}\right]\right\}=\\ {}\kern2.16em \left\{\left[1/{\left(1+r\right)}^1\right]\right.\times \left[{NHGDPPC}_{Int\$}\right]\times \left.\left[{NTDD}_{60-69}\right]\right\}+\\ {}\kern2.16em \left\{\left[1/{\left(1+r\right)}^2\right]\right.\times \left[{NHGDPPC}_{Int\$}\right]\times \left.\left[{NTDD}_{60-69}\right]\right\}+\dots +\\ {}\kern2.16em \left\{\left[1/{\left(1+r\right)}^k\right]\right.\times \left[{NHGDPPC}_{Int\$}\right]\times \left.\left[{NTDD}_{60-69}\right]\right\}\end{array}} $$
$$ {\displaystyle \begin{array}{l}{VHLLost}_{\ge 70}=\sum \limits_{i=1}^k\left\{\left[1/{\left(1+r\right)}^k\right]\right.\times \left[{NHGDPPC}_{Int\$}\right]\times \left.\left[{NTDD}_{\ge 70}\right]\right\}=\\ {}\kern2.16em \left\{\left[1/{\left(1+r\right)}^1\right]\right.\times \left[{NHGDPPC}_{Int\$}\right]\times \left.\left[{NTDD}_{\ge 70}\right]\right\}+\\ {}\kern2.16em \left\{\left[1/{\left(1+r\right)}^2\right]\right.\times \left[{NHGDPPC}_{Int\$}\right]\times \left.\left[{NTDD}_{\ge 70}\right]\right\}+\dots +\\ {}\kern2.16em \left\{\left[1/{\left(1+r\right)}^k\right]\right.\times \left[{NHGDPPC}_{Int\$}\right]\times \left.\left[{NTDD}_{\ge 70}\right]\right\}\end{array}} $$

Where: 1/(1 + r) k is the discount factor that converts future VHLLostinto today’s dollars; r is an interest rate that measures the opportunity cost of lost livelihood or output; \( \sum \limits_{i=1}^k \) is the summation from year i to k; i is the first year of life lost, and k is the final year of the total number of YLLs per NTDD, which is obtained by subtracting the mean age at death for NTD-related causes from global maximum average life expectancy; NHGDPPCInt$ is per capita non-health GDP in PPP, which is obtained by subtracting per-capita total health expenditure (PCTHE) from per-capita GDP (GDPPCInt$ ); NTDD0 − 4 is the number of NTDDs among those aged 0–4 years in country m in 2015; NTDD5 − 14 is the number of NTDDs among those aged 5–14 years in country m in 2015; NTDD15 − 29 is the number of NTDDs among those aged 15–29 years in country m in 2015; NTDD30 − 49 is the number of NTDDs among those aged 30–59 years in country m in 2015; NTDD50 − 59is the number of NTDDs among those aged 50–59 years in country m in 2015;NTDD60 − 69is the number of NTDDs among those aged 60–69 years in country m in 2015; and NTDD≥70 is the number of NTDDs among those aged 70 years and above in country m in 2015. The base year to which future losses in value of human life were discounted was 2015. The discount factor used for losses occurring at diverse years hinge on both the number of years, k, over which discounting is done and the discount rate (r) [76, 8183].

Data sources

The abovementioned eight equations were estimated using data from the WHO, International Labour Organization (ILO) and International Monetary Fund (IMF) sources. The parameters used in the analysis and data sources are summarised in Table 2.

Data analysis

The analysis was done using Excel software (Microsoft, New York) following a number of steps:
  • Step 1: The countries were categorised into three economic groups for comparative purposes, as shown in Table 2. Group 1: 10 high- and upper-middle-income countries; Group 2: 17 lower-middle-income countries; and Group 3: 27 low-income countries [1].

  • Step 2: The eight formulas outlined above were built into a spreadsheet for each of the 53 countries.

  • Step 3: The NTDDs by country and age brackets were downloaded from the WHO Global Health Estimates 2015 [4] (see Additional file 2). The methodological details of how the number of deaths for each NTD by age bracket per country was calculated are detailed in a WHO source [84].

  • Step 4: The life expectancy data used for all countries were sourced from Table 2.1 of the WHO document entitled “WHO methods and data sources for global burden of disease estimates 2000 – 2015” [85] (see Additional file 3). Thus, following this estimation, instead of using individual African country’s life expectancies, we used the highest global projected life expectancies achieved by women in Japan and the Republic of Korea, with a life expectancy at birth of 91.9 years [85]. According to the WHO, this represents the maximum life span of an individual in good health who is not exposed to avoidable health risks or severe injuries, and receives appropriate health services. The WHO [85] provides maximum life spans for 20 age groups, while our study has seven age groups. The maximum life spans (in years) for the seven age groups under consideration in this study were obtained as follows:

  1. a)

    0–4 is the average of the highest global life spans for neonatal (91.93 years), post-neonatal (91.55 years) and 1–4 years (89.41 years), i.e. (91.93 + 91.55 + 89.41)/3 = 90.96 years;

  2. b)

    5–14 is the average of the highest global life spans for those aged 5–9 and 10–14 years, i.e. (84.52 + 79.53)/2 = 82.025 years;

  3. c)

    15–29 is the average of the highest global life spans for those aged 15–19, 20–24 and 25–29 years, i.e. (74.54 + 69.57 + 64.6)/3 = 69.57 years;

  4. d)

    30–49 is the average of the highest global life spans for those aged 30–34, 35–39, 40–44 and 45–49 years, i.e. (59.63 + 54.67 + 49.73 + 44.81)/4 = 52.21 years;

  5. e)

    50–59 is the average of the highest global life spans for those aged 50–54 and 55–59 years, i.e. (39.92 + 35.07)/2 = 37.495 years;

  6. f)

    60–69 is the average of the highest global life spans for those aged 60–64 and 65–69 years, i.e. (30.25 + 25.49)/2 = 27.87 years;

  7. g)

    70+ years is the average of the highest global life spans for those aged 70–74, 75–79, 80–84 and 80 + years, i.e. (20.77 + 16.43 + 12.51 + 7.6)/4 = 14.3275 years.

Table 2

Parameters used in the analysis




Mortality in 2015

Numbers and ratios of NTDDs occurring in the seven age brackets, per country

WHO [4]


Global maximum YLLs for each of the seven age brackets

WHO [85]

Legal minimum age for employment

15 years

ILO [86]

Population in 2015

Population per country

WHO [2]

Average economic output per person in each of the 53 African countries with data in 2015

GDP per capita per country

IMF [3]

Expenditure on health in 2015

Projected 2015 total expenditure on health (THE) per person per country in Africa (projected using 2013 and 2014 THE data)

WHO [87]

Given that the legal minimum working age is 15 years, as according to the ILO [86], only the years above 14 were considered when calculating the productive YLLs for the 0–4 and 5–14 years’ age brackets.
  • Step 5: The YLLs obtained in Step 4 were discounted at a discount rate of 3%.

  • Step 6: The national and per-capita GDP in Int$ (or PPP) were downloaded from the IMF website [3].

  • Step 7: The non-health per-capita GDP in Int$ or PPP (NHGDPPC) was estimated (see Additional file 4). The NHGDPPC was obtained by subtracting per-capita total health expenditure from per-capita GDP [87].

  • Step 8: Sensitivity analysis was conducted. This study used a 3% discount rate, which has been used in past economic evaluation and health systems studies [67, 73, 84, 85, 8890]. In order to gauge the sensitivity of the value of human life estimates to discount rate, eqs. (1) to (8) were re-estimated with 5% and 10% discount rates. Those equations were subsequently re-estimated assuming Africa’s maximum life expectancy of 75.6 years (i.e. life expectancy for Algeria) for all countries instead of their actual life expectancies to determine the impact on the value of human life estimates.

  • Step 9: Each country’s population and NTDDs were sorted into three economic groups, i.e. Group 1, Group 2 and Group 3 (see Table 3).

  • Step 10: The value of human life estimates for various countries were grouped into the three groups and descriptive statistics were calculated.

  • The process of estimating value of human life lost due to NTDDs is illustrated in Additional file 5 using actual data on Egypt.

Table 3

Total population and NTDDs by economic group in Africa

Economic class

Population in 2015

NTDDs in 2015

High-income and upper-middle-income countries (Group 1)

134 117 000

3 225

Lower-middle-income countries (Group 2)

509 004 000

26 888

Low-income countries (Group 3)

541 379 000

37 747


1 184 500 000

67 860

Source: WHO [2]

Ethics approval and consent to participate

This study did not require approval from the Meru University of Science and Technology Institutional Research Ethics Review Committee because it did not involve the use of any animal, or human data or tissue. In addition, the study did not involve any participation of human beings. It was based completely on secondary statistical data published on the WHO, World Bank and IMF websites.


An estimated 67 860 (1.23%) of communicable, maternal, perinatal and nutritional conditions deaths resulted from 16 NTDs [4]. About 8.1% of these deaths occurred among those aged 0–4 years, 16.7% among those aged 5–14 years, 21.4% among those aged 15–29 years, 23.8% among those aged 30–49 years, 10.1% among those aged 50–59 years, 10.2% among those aged 60–69 years, and 9.7% among those aged 70 years and above. Thus, 55.3% of NTDDs occurred among the most productive age bracket of 15–59 years.

About 4.75% of the NTDDs were borne by the high- and upper-middle-income countries (Group 1), 39.62% by the lower-middle-income countries (Group 2) and 55.62% by the low-income countries (Group 3). The mean NTDDs per country was 1257 (STD = 2329); varying from a minimum of 1 in Seychelles to a maximum of 13 944 in Nigeria. The non-health GDP per capita in the continent was Int$ 5724 (STD = 7233), ranging from Int$ 739 in the Democratic Republic of the Congo (DRC) to Int$ 37 598 in Equatorial Guinea. The continental mean total expenditure on health in 2015 was Int$ 315 (STD = 325), varying from Int$ 24.7 in Madagascar to Int$ 1200 in South Africa.

Value of human life loss attributable to NTDs

The 67 860 NTDDs led to a loss of human life worth Int$ 5 112 472 607; which is approximately 0.1% of the Continent’s GDP in 2015 (see Table 4). Almost 14.6% of the loss was suffered by Group 1, 57.7% by Group 2 and 27.7% by Group 3 countries. The mean value of human life lost was Int$ 75 339 per NTDD. The expected value of human lives lost across the continent varied widely, from Int$ 185 766 in Sao Tome and Principe to Int$ 1 625 450 009 in Nigeria. The potential value of human lives lost was under Int$ 10 million in 16 countries, between Int$ 10 million and Int$ 50 million in 21 countries, between Int$ 51 million and Int$ 100 million in one country, and over Int$ 100 million in 15 countries.
Table 4

Present value of human lives lost due to NTDDs in Africa (Int$ or PPP, in 2015)

Summary of indirect costs

High-income and upper-middle- income countries

Sub-total cost (Int$)

Lower-middle- income countries

Sub-total cost (Int$)

Low-income countries

Sub-total cost (Int$)

Grand total cost (Int$)

(1). Total present value of NTDDs

745 815 366

2 951 569 697

1 415 087 545

5 112 472 607

(2). Average present value per NTDD

231 278

109 771

37 489

75 339

(3). Average present value per person in population





% of grand total





Out of the total loss in the entire continent, 19.1% was borne by those aged 0–4 years, 21.9% by those aged 5–14 years, 28.4% by those aged 15–29 years, 25.8% by those aged 30–49 years, 4% by those aged 50–59 years, 0.5% by those aged 60–69 years, and 0.2% by those aged 70 years and above. Thus, those in the most productive age bracket of 15–59 years bore 58.2% of the losses.

Value of human life lost among group 1 countries

The 3225 NTDDs in Group 1 countries resulted in an expected loss of Int$ 745 815 366 in terms of the value of human life in 2015, which was equal to 0.04% of the group’s total GDP. The total value of human lives lost varied greatly, from Int$ 496 645 in Seychelles to Int$ 321 053 534 in Angola. Figure 1 shows the distribution of Group 1’s total value of human lives lost. Approximately 74.2% of the loss was borne by Angola and South Africa.
Fig. 1

Value of human lives lost due to NTDDs in high-income and upper-middle-income countries (Group 1) of Africa (Int$, in 2015)

Group 1’s total present value of human life lost was distributed as follows across the NTDs: 42% schistosomiasis, 25.8% cysticercosis, 15.6% rabies, 5.2% ascariasis, 3.7% African trypanosomiasis, 3.3% leprosy, 2.3% leishmaniasis, 1.2% dengue, and 0.9% echinococcosis (see Table 5). Thus, the first three diseases accounted for 83.3% of losses incurred by Group 1.
Table 5

Distribution of present value of human lives lost in Africa across economic groups and NTDs (in 2015 Int$ or PPP)


Group 1 Deaths in 2015

Group 1 Present Values in 2015 INT$


Group 2 Deaths in 2015

Group 2 Present Values in 2015 INT$


Group 3 Deaths in 2015

Group 3 Present Values in 2015 INT$


African Trypanosomiasis


28 205 045



17 233 681



192 392 224


Chagas disease



313 029 760


10 798

1 185 282 070


10 645

399 067 659




17 107 978



270 799 302



124 875 000


Lymphatic filariasis




192 349 158



725 570 891



333 912 225




6 473 289



19 319 285



7 085 372




9 016 367



38 748 340



11 658 999





116 519 202



530 731 507



258 035 011




38 608 545



102 304 398



22 643 200



Hookworm disease

Food-borne trematodes



24 506 023



61 580 222



65 417 855




745 815 366


26 888

2 951 569 697


37 747

1 415 087 545


Value of human life lost among group 2 countries

The 26 888 NTDDs in Group 2 countries resulted in an expected total loss of Int$ 2 951 569 697 in the value of human life in 2015, or 0.09% of the group’s total GDP. The loss varied from Int$ 185 766 in Sao Tome and Principe to Int$ 1 625 450 009 in Nigeria. Figure 2 shows the distribution of Group 2’s total value of human lives lost. Approximately 55.1% of Group 2’s expected loss was borne by Nigeria alone. About 83% of Group 2’s expected loss was borne by Cote d’Ivoire, Egypt, Nigeria and Sudan.
Fig. 2

Value of human lives lost due to NTDDs in lower-middle-income countries (Group 2) of Africa (Int$, in 2015)

Group 2’s total present value of human life lost was distributed as follows across the NTDs: 40.0% schistosomiasis, 24.6% cysticercosis, 18% rabies, 9.2% leishmaniasis, 3.5% ascariasis, 2.1% leprosy, 1.3% dengue, 0.7% echinococcosis, and 0.6% African trypanosomiasis. Therefore, the first three diseases were responsible for 82.6% of the Group 2 losses (see Table 5).

Value of human life lost among group 3 countries

The estimated 37 747 NTDDs that occurred among Group 3 countries led to a total expected loss in value of human life of Int$ 1 415 087 545 in 2015, which is equivalent to 0.2% of the group’s total GDP. The expected loss ranged from Int$ 725 391 in Comoros to Int$ 338 485 350 in Ethiopia, which bore 23.9% of the group’s loss. The distribution of Group 3’s total value of human lives lost is depicted in Fig. 3. The DRC, Ethiopia, South Sudan, Tanzania and Uganda together accounted for 63% of the expected loss in this group. It is interesting to note that although Group 3 had 10 000 more NTDDs than Group 2, the value of human lives lost of Group 2 was higher than that of Group 3 by Int$ 1.54 billion because Group 2 had higher per-capita GDP.
Fig. 3

Value of human lives lost due to NTDDs in low-income countries (Group 3) of Africa (Int$, in 2015)

Group 3’s total present value of human life lost was distributed as follows across the NTDs: 28.2% schistosomiasis, 23.7% cysticercosis, 18.2% rabies, 13.6% African trypanosomiasis, 8.8% leishmaniasis, 4.6% leprosy, 1.6% ascariasis, 0.8% dengue and 0.5% echinococcosis. Thus, the first three diseases were responsible for 70% of Group 3’s losses (see Table 5).

Average value of human life losses

The mean value of human lives lost per NTDD and per person in the population for the 53 countries are displayed in Table 6. These values were obtained by dividing each group’s total value of human life lost by its total NTDDs. The mean value of human life lost per person in the population for each group was calculated by dividing the group’s total value of human life lost by its population.
Table 6

Discounted value of human lives lost due to NTDDs among continental Africa countries (Int$ or PPP, in 2015)


(A) Population


(C) Total value of all human lives lost due to NTDs (Int$)

(D) Value of human life lost per NTDD (Int$)

[D = (C/B)]

(E) Value of human life lost per person in population (Int$)

[E = (C/A)]


39 667 000


76 687 914

304 735



25 022 000


321 053 534

173 188



10 880 000


28 473 736

47 543



2 262 000


7 430 499

341 854


Burkina Faso

18 106 000


45 761 966

42 074



11 179 000


14 673 682

19 547



23 344 000


115 191 263

76 543


Cape Verde

521 000


642 650

149 761


Central African Republic

4 900 000


12 132 085

16 357



14 037 000


106 702 194

64 305



788 000


727 391

35 531


Congo Republic of

4 620 000


26 065 572

148 966


Cote d’Ivoire

22 702 000


231 097 654

83 803



77 267 000


140 486 238

19 250


Equatorial Guinea

845 000


42 493 865

895 595



5 228 000


6 786 209

24 350



99 391 000


338 483 350

46 275



1 725 000


47 986 750

447 687


Gambia The

1 991 000


2 574 353

37 974



27 410 000


119 008 952

103 489



12 609 000


34 402 618

27 069



1 844 000


3 193 144

33 478



46 050 000


114 657 578

78 047



2 135 000


1 897 047

66 004



4 503 000


3 459 176

18 030



24 235 000


38 131 704

37 481



17 215 000


13 198 778

23 832



17 600 000


43 813 514

43 425



4 068 000


14 928 594

97 022



1 273 000


3 212 952

441 942



27 978 000


41 035 562

26 597



2 459 000


4 305 273

234 472



19 899 000


27 871 413

19 517



182 202 000

13 944

1 625 450 009

116 572



11 610 000


17 313 494

42 472


Sao Tome and Principe

190 000


185 766

65 785



15 129 000


28 758 809

60 629



96 000


496 645

683 843


Sierra Leone

6 453 000


23 115 300

34 786


South Africa

54 490 000


232 433 738

263 625


South Sudan

12 340 000


124 210 140

41 228



1 287 000


4 630 328

197 374



53 470 000


175 770 061

77 176



7 305 000


15 077 774

34 028



39 032 000


112 108 332

47 836



16 212 000


48 509 819

78 483



15 603 000


16 826 522

48 696



888 000


2 285 624

67 853



91 508 000


169 948 068

269 620



6 278 000


9 714 196

278 383



34 378 000


35 758 333

204 524



40 235 000


432 348 755

103 325



11 254 000


8 963 687

266 963


The value of human life lost per NTDD was Int$ 231 278 for Group 1, Int$ 109 771 for Group 2 and Int$ 37 489 for Group 3. The mean value of human life lost per person in the population was Int$ 5.6 for Group 1, Int$ 5.8 for Group 2 and Int$ 2.6 for Group 3 (see Table 4). The mean value of human life lost per NTDD in Group 1 was over two times that of Group 2 and almost six times that of Group 3.

The main determinant of expected value of human life lost is the magnitude of GDP per person. For instance, even if deaths in Group 1 countries such as Botswana, Libya, Mauritius and Seychelles were only 22, 35, 7 and 1, respectively, the value of human life lost per NTDD for these countries were considerable at Int$ 341 854 for Botswana, Int$ 278 383 for Libya, Int$ 441 942 for Mauritius and Int$ 683 843 for Seychelles. Group 3 countries with comparatively higher number of NTDDs such as for the DRC with 7298 deaths, Ethiopia with 7315 deaths, South Sudan with 3013 deaths and Uganda with 2344 deaths have relatively lower values of human life lost per NTDD of Int$ 19 250, Int$ 46 275, Int$ 41 228 and Int$ 47 836, respectively.

Sensitivity analysis results

The use of a 5% discount rate resulted in a reduction in the total value of human life loss of Int$ 1 446 559 015 (28.3%) and the mean value of human life loss per NTDD by Int$ 21 317. Application of a 10% discount rate reduced the overall total value of human life loss by Int$ 3 030 347 733 (59.3%) and the mean value of human life loss per NTDD by Int$ 44 656.


The estimated total value of human life loss attributed to NTDDs is about 0.1% of the 2015 GDP of the 53 African countries. As demonstrated by the sensitivity analysis, the magnitude of the total value of human life loss hinges on the discount rate [7375].

The total value of human life loss attributed to NTDDs is higher than the Int$ 1.69 billion for diabetes in Africa [72]. However, it was lower than that the Int$ 5.53 billion for maternal mortality and Int$ 50.4 billion for tuberculosis deaths in Africa [75, 76].

It may be argued that there is not much point to continue investing in NTDs, which cause a relatively lower number of deaths and productivity losses compared to, for example, maternal mortality and tuberculosis mortality. Such critiques should take into account that while NTDs are not a major cause of death, they have life-long debilitating effects on health-related quality of life of populations living in endemic areas [9195], educational achievements of children, worker productivity and agricultural outputs [6, 92, 96, 97].

There are six main arguments for continued (and probably increased) investment to control, eliminate and eventually eradicate NTDs. First, in line with the 1948 UN Universal Declaration of Human Rights, it is the right of every person living in NTD-endemic areas to have unconstrained access to all effective preventive and treatment interventions [98, 99]. Thus, we concur with Molyneux [100] that the “continuing advocacy for the relevance of control or elimination of NTDs must be placed in the context of universal health coverage and access to donated essential medicines for the poor as a [human] right” (p. 1).

Second, the resources required for implementing the regional strategic plan for eliminating NTDs in the African region have been estimated at US$ 2.57 billion over a six-year period, which translates to US$ 428.33 million per year [101, 102]. This cost of implementing national-level “NTD Master Plans” for controlling NTDs is by far much lower than our estimated NTD-related productivity losses of Int$ 5.1 billion.

Third, effective medicines for treating all NTDs are available and a sufficient amount of donated drugs has been pledged by their manufacturers to meet the needs in endemic countries [102, 103].

Fourth, even though NTDs are not a major cause of death, every year they lead to a substantive loss of disability-adjusted life years (DALYs) in Africa. For example, the WHO estimated that in 2015, the African continent lost 10.3 million DALYs due to neglected parasitic diseases and intestinal nematodes [104].

Fifth, global and continental plans and programmes for combating NTDs exist. They provide detailed guidance on the cost-effective NTD interventions that individual countries should invest in. These plans include: the WHO global strategy 2015–2020 on water, sanitation and hygiene for accelerating and sustaining progress on neglected tropical diseases [105]; regional strategy on NTDs [106]; regional strategic plan for NTDs [106]; roadmap for accelerating work to overcome the global impact of neglected tropical diseases [107]; and the global plan to combat neglected tropical diseases 2008–2015 [108]. In 2015, the Expanded Special Project for Elimination of Neglected Tropical Diseases was established in Africa [109].

Sixth, continental and global political commitment exists for ending the morbidity and mortality from NTDs. In January 2014, the Twenty-Fourth Ordinary Session of the African Union Executive Council adopted the Continental Framework on the Control and Elimination of NTDs in Africa by 2020 and committed to using it for developing and revising national NTD plans [110]. In 2013, the World Health Assembly, through resolution WHA66.12, adopted a comprehensive global strategy for combatting NTDs [111]. In the same year, the Sixty-Third Regional Committee for Africa through resolution AFR/RC63/R6 adopted both the regional strategy and the strategic plan on NTDs [112]. The African Union decisions and WHO Regional Committee for Africa resolutions urge African countries and their partners to commit more resources and use them efficiently to implement the Continental Framework on the Control and Elimination of NTDs through national NTD plans.


There are seven broad limitations of the current study. First, some costs were omitted. For example, direct costs of NTD prevention programmes, and diagnosis and treatment services were not taken into account because the current study focused on years of life lost due to premature mortality. The study also excluded the indirect costs of productive labour time lost due to morbidity, including cost of time spent seeking treatment, reduced level of performance of activities/functions of daily living, and time expended by caregivers (family and friends) and those accompanying the sick to sources of care, e.g. health facilities, private pharmaceutical shops, traditional healers. The intangible/psychological costs related to stigmatisation, discrimination, pain, anxiety and bereavement were also omitted.

Second, to date there is no consensus in the published literature on the discount rate that should be applied in health sector studies. In this study, we used discount rate of 3%, which has been applied frequently in past health-related studies [81, 113115].

Third, there is no agreement in literature about whether mortality occurring at different age groups should be weighted differently. In our study, we assumed all life to be intrinsically valuable and thus a year lost in an age group was considered to be of equal value [116]. This is why the current study used per-capita GDP to value YLLs at any age group.

Fourth, various authors have underscored a few weaknesses inherent in the use of per-capita GDP as a measure of societal economic and wellbeing: (a) per-capita GDP is an average value, which is distorted by high-income earners and corporate supernormal profits, and does not reflect distribution of income, consumption and wealth [117]. Therefore, if a country’s GDP distribution is skewed, a small wealthy class can increase per-capita GDP substantially while the majority of the population does not experience any economic and social progress [117]. (b) Per-capita GDP does not factor in the negative externalities of goods and services production and delivery processes, e.g. depletion of natural resources, air pollution from carbon emissions of airplanes and vehicles, global warming, and contamination of water with industrial waste [117]. (c) The value of household and other unpaid work is not measured in the system of national accounts that produces GDP. A substantial burden of unpaid domestic work (preparing food, cleaning and maintaining the home) and unpaid care work (care a person provides to their own family and household members) in Africa is borne by women [118121]. We concur with Hirway [121] that the exclusion of unpaid domestic and caring work from national accounts and from the conventional economy is not justifiable, as both contribute to the conventional economy.

Fifth, a number of weaknesses characterise the lost output approach or HCA: (a) It assumes that the objective of health care is getting sick people back to productive employment. However, there are other objectives, such as preventing morbidity and death so that people can enjoy life (flourish), enjoy leisure and perform non-economic societal functions, etc. (b) In its pure form, the HCA would value the lives of pensioners (elderly), full-time homemakers and non-working children at zero. In this study, we value all lives using per-capita GDP prevailing in each country. (c) The HCA does not capture intangible psychological costs of NTDs, e.G. stigma, pain, bereavement, anxiety and suffering [122, 123].

Sixth, the values of life loss estimates reported in this paper are not a guide to setting priorities in the research, prevention and treatment of NTDs [124, 125]. The estimated value of human lives lost due to NTDs are only meant for use in raising public awareness and advocacy with ministries of finance in African countries on the magnitudes of potential economic losses arising from mortality associated with NTDs. Therefore, we are cognisant of the fact that setting priorities in NTD research, prevention and treatment must be guided by economic evaluation evidence on costs and consequences of competing research, prevention and treatment strategies [81, 82].

Seventh, it is common knowledge that vital registration systems in many countries in Africa are either non-existent or very weak. That is why the deaths and burden of disease estimates reported by international organisations are often projections based on second-best approaches. Thus, it is usually not possible to verify the coverage and quality of secondary mortality data among the analysed countries.


Even though NTDs are not a major cause of death, they impact negatively on the productivity of those affected throughout their life-course. Thus, the case for investing in NTD control should also be influenced by the value of NTD morbidity, availability of effective donated medicines, human rights arguments and need to achieve the NTD-related target 3.3 of the UN SDG 3 (on health) by 2030.

In order for the African continent to have a fair chance of ending the epidemic of NTDs by 2030, as envisioned in SDG 3, the national governments, African Union, Regional Economic Communities and all partners need to continue fighting the war against NTDs until they are all controlled, eliminated, eradicated and eventually extinct from the continent. As long as corruption and lack of accountability remain endemic due to weak leadership [126129] and governance [130132], the war against NTDs (and other causes of ill-health) is unlikely to be won. Thus, African governments and development partners need to continue their efforts to fully implement the Paris Declaration on Aid Effectiveness and the Accra Agenda for Action [133] to ensure strategic policy frameworks exist and are combined with effective integration, coordination, oversight (to assure efficiency), coalition building, the provision of appropriate regulations and incentives, attention to system-design and accountability [134136].



Per capita GDP in international dollars


Per capita non-health GDP in PPP

VHLLost 0 − 4

Value of human lives lost among those aged 0–4 years

VHLLost 15 − 29

Value of human lives lost among those aged 15–29 years

VHLLost 30 − 49

Value of human lives lost among those aged 30–49 years

VHLLost 50 − 59

Value of human lives lost among those aged 50–59 years

VHLLost 5 − 14

Value of human lives lost among those aged 5–14 years

VHLLost 60 − 69

Value of human lives lost among those aged 60–69 years

VHLLost ≥70

Value of human lives lost among those aged 70 years and above


Disability-adjusted life year


Democratic Republic of the Congo


Gross domestic product


International Labour Organization


International Monetary Fund


International dollars


neglected tropical disease


NTD death


Per-capita total health expenditure


Purchasing power parity


Rate of discount of future losses


United Nations


Value of human lives lost


World Health Organization


Year of life lost



Jehovah-Jireh met all our needs in the process of writing this paper. We dedicate this article to all those who died prematurely from NTDs; all those living with NTDs; the African Union (and its organs) and Regional Economic Communities; the WHO; and all the leaders, health workers, communities, researchers, educators, journal editors and health development partners who are unremittingly fighting to make NTDs extinct in Africa. This paper contains solely the views of the authors and does not represent the views or policies of the Meru University of Science and Technology.


This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Availability of data and materials

The datasets analysed during this study are outlined in the attached Additional Files.

Additional file 2: Number of NTDDs in Africa in 2015.

Additional file 3: Life expectancies and YLLs per country in Africa in 2015.

Additional file 4: Non-health GDP per capita in Africa in 2015.

Authors’ contributions

JMK and GNM designed the study, conducted the literature review, analysed the data and wrote the paper. All authors approved the final version of the paper for publication.

Ethics approval and consent to participate

Not applicable. This study did not involve the use of any animal or human data or tissue. It was based completely on secondary statistical data published on the WHO and IMF websites.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

Meru University of Science and Technology, Meru, Kenya


  1. World Bank. Country and lending groups – country classification. Washington, D.C. 2016. Accessed 30 Nov 2016.
  2. World Health Organization (WHO). World Health Statistics 2016. Geneva: WHO; 2016.Google Scholar
  3. International Monetary Fund (IMF). World Economic Outlook Database. Washington, D.C. 2016. Accessed 7 Feb 2017.
  4. WHO. Global Health estimates 2015: Deaths by cause, age, sex, by country and by region, 2000-2005. Geneva: WHO; 2016.Google Scholar
  5. Remme JHF, Feenstra P, Lever PR, Medici AC, Morel CM, Noma M, et al. Tropical diseases targeted for elimination: Chagas disease, lymphatic Filariasis, Onchocerciasis, and leprosy. In: Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, Jha P, Mills A, Musgrove P, editors. Disease control priorities in developing countries. 2nd ed. New York: Oxford University Press; 2006. p. 433–50.Google Scholar
  6. Norris J, Adelman C, Spantchak Y, Marano K. Social and economic impact review on neglected tropical diseases. Washington, D.C.: Hudson Institute’s Center for Science in Public Policy & The Global Network for Neglected Tropical Diseases an initiative of the Sabin Vaccine Institute; 2012.Google Scholar
  7. Hotez PJ, Fenwick A, Savioli L, Molyneux DH. Rescuing the bottom billion through control of neglected tropical diseases. Lancet. 2009;373:1570–5.PubMedView ArticleGoogle Scholar
  8. WHO. First WHO report on neglected tropical diseases: working to overcome the global impact of neglected tropical diseases. Geneva: WHO; 2010.Google Scholar
  9. WHO. Sustaining the drive to overcome the global impact of neglected tropical diseases: second WHO report on neglected diseases. Geneva: WHO; 2013.Google Scholar
  10. National Research Council. The causes and impacts of neglected tropical and Zoonotic diseases: opportunities for integrated intervention strategies - workshop summary. Washington, DC: The National Academies Press; 2011.Google Scholar
  11. Samuels F, Pose R. Why neglected tropical disease matter in reducing poverty. Development progress. Working paper 03. London: ODI; 2013.Google Scholar
  12. Quansah E, Sarpong E, Karikari TK. Disregard of neurological impairments associated with neglected tropical diseases in Africa. eNeurologicalSci. 2016;3:11–4.PubMedView ArticleGoogle Scholar
  13. African Union (AU). Neglected tropical diseases in the Africa region. Sixth conference of AU ministers of health, Addis Ababa, Ethiopia, 22–26 April 2013. Addis Ababa: AU; 2013.Google Scholar
  14. United Nations (UN). Seventieth session of the United Nations general assembly resolution a/RES/70/1. Transforming our world: the 2030 agenda for sustainable development. New York: UN; 2015.Google Scholar
  15. Frick KD, Basilion E, Hanson C, Colchero M. Estimating the burden and economic impact of trachomatous visual loss. Ophthalmic Epidemiol. 2003;10(2):121–32.PubMedView ArticleGoogle Scholar
  16. Frick KD, Hanson CL, Jacobson GA. Global burden of trachoma and economics of the disease. Am J Trop Med Hyg. 2003;69((5) suppl 1):1–10.PubMedView ArticleGoogle Scholar
  17. Ramaiah KD, Das PK, Michael E, Guyatt H. The economic burden of lymphatic filariasis in India. Parasitol Today. 2000;16(6):251–3.PubMedView ArticleGoogle Scholar
  18. Boelaert M, Meheus F, Robays J, Lutumba P. Socio-economic aspects of neglected tropical diseases: sleeping sickness and visceral leishmaniasis. Pathog Glob Health. 2010;104(7):535–42.Google Scholar
  19. King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic helminthic infection: a meta-analysis of disability-related outcomes in endemic schistosomiais. Lancet. 2005;365:1561–9.PubMedView ArticleGoogle Scholar
  20. Meltzer M. Using disability adjusted life years to assess the economic impact of dengue in Puerto Rico: 1984-1994. Am J Trop Med Hyg. 1998;59(2):265–71.PubMedView ArticleGoogle Scholar
  21. Von Allmen SD, Lopez-Correa RH, Woodall JP, Morens DM, Chiriboga J, Casta-Valez A. Epidemic dengue fever in Puerto Rico, 1977: a cost analysis. Am J Trop Med Hyg. 1979;28:1040–4.PubMedView ArticleGoogle Scholar
  22. Kouri GP, Guzman MG, Bravo JR, Triana C. Dengue haemorrhagic fever/dengue shock syndrome: lessons from the Cuban epidemic, 1981. Bull World Health Organ. 1989;67:375–80.PubMedPubMed CentralGoogle Scholar
  23. Sornmani S, Okanurak K, Indaratna K. Social and economic impact of dengue haemorrhagic fever in Thailand. Bangkok: Social and Economic Research Unit, Mahidol University; 1995.Google Scholar
  24. Gyapong JO, Gyapong M, Evans DB, Aikins MK, Adjei S. The economic burden of lymphatic filariasis in northern Ghana. Ann Trop Med Parasitol. 1996;90(1):39–48.PubMedView ArticleGoogle Scholar
  25. Meheus F, Abuzaid AA, Baltussen R, Younis BM, Balasegaram M, Khalil EAG, et al. The economic burden of visceral Leishmaniasis in Sudan: an assessment of provider and household costs. Am J Trop Med Hyg. 2013;89(6):1146–53.PubMedPubMed CentralView ArticleGoogle Scholar
  26. Rijal S, Koirala S, Stuyft PV, Boelaert M. The economic burden of visceral leishmaniasis in Nepal. Trans R Soc Trop Med Hyg. 2006;100(9):839–41.View ArticleGoogle Scholar
  27. Knobel DL, Cleaveland S, Coleman PG, Fevre EM, Meltzer MI, Miranda MEG, et al. Re-evaluating the burden of rabies in Africa and Asia. Bull World Health Organ. 2005;83:360–8.PubMedPubMed CentralGoogle Scholar
  28. Ogochukwu I, Onwujekwe O, Uzochukwu B, Ajuba M, Okonkwo P. Exploring consumer perceptions and economic burden of onchocerciasis on households in Enugu state, south-East Nigeria. PLoS Negl Trop Dis. 2015;9(11):e0004231.View ArticleGoogle Scholar
  29. Lee BY, Bacon KM, Bottazzi ME, Hotez PJ. Global economic burden of Chagas disease: a computational simulation model. Lancet Infect Dis. 2013;13(4):342–8.PubMedPubMed CentralView ArticleGoogle Scholar
  30. Chandler DJ, Hansen KS, Mahato B, Darlong J, John A, Lockwood DNJ. Household costs of leprosy reactions (ENL) in rural India. PLoS Negl Trop Dis. 2015;9(1):e0003431.PubMedPubMed CentralView ArticleGoogle Scholar
  31. Shaw APM. Economics of African trypanosomiais. In: Maudlin I, Holmes PH, Miles MA, editors. The Trypanosomiasis. London: CAB International; 2004. p. 369–402.View ArticleGoogle Scholar
  32. Conteh L, Engels T, Molyneux D. Socioeconomic aspects of neglected tropical diseases. Lancet. 2010;375:239–47.PubMedView ArticleGoogle Scholar
  33. Wright WH. A consideration of the economic impact of schistosomiasis. Bull World Health Organ. 1972;47(5):559–65.PubMedPubMed CentralGoogle Scholar
  34. Mooney GH. Valuing human life in health service delivery policy. Nuffield/York portfolios. Folio 3. Nuffield: Nuffield Provincial Hospitals Trust; 1983. p. 1–12.Google Scholar
  35. Linnerooth J. The value of human life: a review of the models. Econ Inq. 1979;17(1):52–74.PubMedView ArticleGoogle Scholar
  36. Mooney GH. The valuation of human life. London: Macmillan; 1977.View ArticleGoogle Scholar
  37. Jones-Lee MW. The value of life and safety. Amsterdam: North Holland; 1982.Google Scholar
  38. Petty W. Political Arithmetrick, or a discourse concerning the extent and value of lands, people, buildings, etc. London: Robert Caluel. p. 1699.Google Scholar
  39. Fein R. Economics of mental illness. New York: Basic Books; 1958.View ArticleGoogle Scholar
  40. Mushkin SJ, Collings FA. Economic costs of disease and injury. Public Health Rep. 1959;74:795–809.PubMedPubMed CentralView ArticleGoogle Scholar
  41. Weisbrod B. Costs and benefits of medical research: a case study of poliomyelitis. J Political Econ. 1971;79:527–44.View ArticleGoogle Scholar
  42. Landefeld JS, Seskin EP. The economic value of life: linking theory to practice. Am J Public Health. 1982;72:555–66.PubMedPubMed CentralView ArticleGoogle Scholar
  43. Hoque ME, Mannan M, Long KZ, Al Mamun A. Economic burden of underweight and overweight among adults in the Asia-Pacific region: a systematic review. Tropical Med Int Health. 2016;21(4):458–69.View ArticleGoogle Scholar
  44. Yesudian CAK, Grepstad M, Visintin E, Ferrario A. The economic burden of diabetes in India: a review of the literature. Glob Health. 2014;10:80.View ArticleGoogle Scholar
  45. Walker BF, Muller R, Grant WD. Low Back Pain in Australian Adults: The Economic Burden. Asia Pac J Public Health. 2003;15(2):79–87.Google Scholar
  46. Dror DM, Putten-Rademaker OV, Koren R. Cost of illness: evidence from a study in five resource-poor locations in India. Indian J Med Res. 2008;127:347–61.PubMedGoogle Scholar
  47. John RM, Sung H-Y, Max W. Economic cost of tobacco use in India, 2004. Tob Control. 2009;18:138–43.PubMedPubMed CentralView ArticleGoogle Scholar
  48. Zheng Y, Ji L, Wu J. Cost-of-illness studies of diabetes mellitus in China: a systematic review. Chin J Clin Endocrinol Metab. 2012;28(10):821–5.Google Scholar
  49. Hosung S, Suehyung L, Soo KJ, Jinsuk K, Hong HK. Socioeconomic costs of food-borne disease using the cost-of-illness model: applying the QALY method. J Prev Med Public Health. 2010;43(4):352–61.View ArticleGoogle Scholar
  50. Cooper GJS, Scott DJ. The cost of diabetes in South Auckland. N Z Med J. 1985;98(773):113.PubMedGoogle Scholar
  51. Scott WG, White HD, Scott HM. Cost of coronary heart disease in New Zealand. N Z Med J. 1993;106(962):347–9.PubMedGoogle Scholar
  52. Alzheimer’s New Zealand, Access Economics. The economic cost of arthritis in New Zealand. Wellington: Arthritis New Zealand; 2008.Google Scholar
  53. Easton B. The social costs of tobacco use and alcohol misuse. Wellington: Wellington School of Medicine, Alcohol Advisory Council of New Zealand and Public Health Commission; 1997.Google Scholar
  54. Anis AH, Zhang W, Bansback N, Guh DP, Amarsi Z, Birmingham CL. Obesity and overweight in Canada: an updated cost-of-illness study. Obes Rev. 2010;11(1):31–40.PubMedView ArticleGoogle Scholar
  55. Claubaugh G, Ward MM. Cost-of-illness studies in the United States: a systematic review of methodologies used for direct cost. Value Health. 2008;11:13–21.View ArticleGoogle Scholar
  56. American Diabetes Association. Economic costs of diabetes in the U. S. in 2007. Diabetes Care. 2008;31(3):596–615.View ArticleGoogle Scholar
  57. Sandler RS, Everhart JE, Donowitz M, Adams E, Cronin K, Goodman C, et al. The burden of selected digestive diseases in the United States. Gastroenterology. 2002;122(5):1500–11.PubMedView ArticleGoogle Scholar
  58. Wolf AM, Colditz GA. Current estimates of the economic cost of obesity in the United States. Obes Res. 1998;6(7):97–106.PubMedView ArticleGoogle Scholar
  59. Rice DP. Estimating the costs of illness. Am J Public Health. 1967;57:424–40.View ArticleGoogle Scholar
  60. Hartunian NS, Smart CN, Thompson MS. The incidence and economic costs of cancer, motor vehicle injuries, coronary heart disease, and stroke: a comparative analysis. Am J Public Health. 1980;70:1249–60.PubMedPubMed CentralView ArticleGoogle Scholar
  61. Leal J, Luengo-Fernandez R, Sullivan R, Witjes JA. Economic burden of bladder cancer across the European Union. Eur Urol. 2016;69(3):438–47.PubMedView ArticleGoogle Scholar
  62. Luengo-Fernandez R, Burns R, Leal J. Economic burden of non-malignant blood disorders across Europe: a population-based cost study. Lancet Haematol. 2016;3(8):e371–8.PubMedView ArticleGoogle Scholar
  63. Gordois AL, Toth PP, Quek RG, Proudfoot EM, Paoli CJ, Gandra SR. Productivity losses associated with cardiovascular disease: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2016;16(6):759–69.PubMedView ArticleGoogle Scholar
  64. Ignatyeva VI, Derkach EV, Avxeentyeva MV, Omelyanovsky VV. The cost of melanoma and kidney, prostate, and ovarian cancers in Russia. Value Health Reg Issues. 2014;4C:58–65.View ArticleGoogle Scholar
  65. Klimes J, Vocelka M, Sedova L. Medical and productivity costs of rheumatoid arthritis in the Czech Republic: cost-of-illness study based on disease severity. Value Health Reg Issues. 2014;4C:75–81.View ArticleGoogle Scholar
  66. Hillemanns P, Breugelmans JG, Gieseking F, Benard S, Lamure E, Littlewood KJ, et al. Estimation of the incidence of genital warts and the cost of illness in Germany: a cross-sectional study. BMC Infect Dis. 2008;8:76.PubMedPubMed CentralView ArticleGoogle Scholar
  67. Kirigia JM, Sambo LG, Yokouide A, Soumbey-Alley E, Muthuri LK, Kirigia DG. Economic burden of cholera in the WHO African region. BMC Int Health Hum Rights. 2009;9:8.PubMedPubMed CentralView ArticleGoogle Scholar
  68. Orem JN, Kirigia JM, Azairwe R, Kasirye I, Walker O. Impact of malaria morbidity on gross domestic product in Uganda. Int Arch Med. 2012;5:12.PubMedPubMed CentralView ArticleGoogle Scholar
  69. Chima RI, Goodman C, Mills A. The economic impact of malaria in Africa: a critical review of the evidence. Health Policy. 2003;63:17–36.PubMedView ArticleGoogle Scholar
  70. Barnett TA, Whiteside A, Desmond C. The social and economic impact of HIV/AIDS in poor countries: a review of studies and lessons. Prog Dev Stud. 2001;1:151–70.View ArticleGoogle Scholar
  71. Russell S. The economic burden of illness for households in developing countries: a review of studies focusing on malaria, tuberculosis and human immunodeficiency virus/acquired immunodeficiency syndrome. Am J Trop Med Hyg. 2004;71:156–61.Google Scholar
  72. Kirigia JM, Sambo HB, Sambo LG, Barry SP. Economic burden of diabetes mellitus in the WHO African region. BMC Int Health Hum Rights. 2009;9:6.PubMedPubMed CentralView ArticleGoogle Scholar
  73. Kirigia JM, Muthuri RDK, Nabyonga-Orem J, Kirigia DW. Counting the cost of child mortality in the World Health Organization African region. BMC Public Health. 2015;15:1103.PubMedPubMed CentralView ArticleGoogle Scholar
  74. Kirigia JM, Masiye F, Kirigia DW, Akweongo P. Indirect costs associated with deaths from the Ebola virus disease in West Africa. Infect Dis Poverty. 2015;4:45.PubMedPubMed CentralView ArticleGoogle Scholar
  75. Kirigia JM, Muthuri RDK. Productivity losses associated with tuberculosis deaths in the World Health Organization African region. Infect Dis Poverty. 2016;5:43.PubMedPubMed CentralView ArticleGoogle Scholar
  76. Kirigia JM, Mwabu GM, Orem JN, Muthuri RDK. Indirect cost of maternal deaths in the WHO African region, 2013. Int J Soc Econ. 2016;43(5):532–48.View ArticleGoogle Scholar
  77. Fourie FCN. How to think and reason in macroeconomics. Cape Town: Juta & Co.; 1999.Google Scholar
  78. Mooney MH. Economics, medicine and health care. New York: Harvester Wheatsheaf; 1977.Google Scholar
  79. WHO. WHO guide to identifying the economic consequences of disease and injury. Geneva: WHO; 2009.Google Scholar
  80. Chisholm D, Stanciole AE, Edejer TTT, Evans DB. Economic impact of disease and injury: counting what matters. BMJ. 2010;340(c924):583–6.Google Scholar
  81. Kirigia JM. Economic evaluation of public health problems in sub-Saharan Africa. Nairobi: University of Nairobi Press; 2009.Google Scholar
  82. Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 1988.Google Scholar
  83. Curry S, Weiss J. Project analysis in developing countries. London: The MacMillan Press LTD; 1993.View ArticleGoogle Scholar
  84. WHO. WHO methods and data sources for country-level causes of death 2000–2015. Global Health estimates technical paper WHO/HIS/IER/GHE/2016.3. Geneva: WHO; 2016.Google Scholar
  85. WHO. WHO methods and data sources for global burden of disease estimates 2000–2015. Global Health estimates technical paper WHO/HIS/IER/GHE/2017.1. Geneva: WHO; 2017.Google Scholar
  86. International Labour Organization (ILO). C138 - minimum age convention, 1973 (no. 138). Geneva: ILO; 1973.Google Scholar
  87. WHO. Global Health expenditure database, Geneva. 2017. Accessed 7 Feb 2017.
  88. Murray CJL. Rethinking DALYs. In: Murray CJL, Lopez AD, editors. The global burden of disease - a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge: Harvard University Press; 1996.Google Scholar
  89. WHO. World health report 2000: health systems: improving performance. Geneva: WHO; 2000.Google Scholar
  90. Murray CJL, David B. Health systems performance assessment: debates, methods and empiricism. Geneva: WHO; 2003.Google Scholar
  91. Adenowo AF, Oyinloye BE, Ogunyinka BI, Kappo AP. Impact of human schistosomiasis in sub-Saharan Africa. Braz J Infect Dis. 2015;19(2):196–205.PubMedView ArticleGoogle Scholar
  92. Fenwick A. Neglected tropical diseases: can we take the ‘neglected’ out of the name? A Global Village. Imperial College International Affairs J. 2010;2:15–8.Google Scholar
  93. Hollingsworth TD, Adams ER, Anderson RM, Atkins K, Bartsch S, Basáñez M-G, et al. NTD Modelling consortium: quantitative analyses and modelling to support achievement of the 2020 goals for nine neglected tropical diseases. Parasit Vectors. 2015;8:630.PubMedPubMed CentralView ArticleGoogle Scholar
  94. Cattand P, Desjeux P, Guzmán MG, Jannin J, Kroeger A, Médici A, et al. Tropical diseases lacking adequate control measures: Dengue, Leishmaniasis, and African Trypanosomiasis. In: Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, Jha P, Mills A, Musgrove P, editors. Disease control priorities in developing countries (DCP2). New York: The World Bank and Oxford University Press; 2006. p. 451–66.Google Scholar
  95. Hotez PJ, Bundy DAP, Beegle K, Brooker S, Drake L, de Silva N, et al. Helminth infections: soil-transmitted Helminth infections and Schistosomiasis. In: Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, Jha P, Mills A, Musgrove P, editors. Disease control priorities in developing countries (DCP2). New York: The World Bank and Oxford University Press; 2006. p. 467–82.Google Scholar
  96. Lenk EJ, Redekop WK, Luyendijk M, Rijnsburger AJ, Severens JL. Productivity loss related to neglected tropical diseases eligible for preventive chemotherapy: a systematic literature review. PLoS Negl Trop Dis. 2016;10(2):e0004397.PubMedPubMed CentralView ArticleGoogle Scholar
  97. Institute of Medicine (US) Forum on Microbial Threats. The causes and impacts of neglected tropical and Zoonotic diseases: opportunities for integrated intervention strategies. Washington (DC): National Academies Press (US); 2011.Google Scholar
  98. UN. Universal declaration of human rights. New York: UN; 1948.Google Scholar
  99. WHO. Neglected diseases: a human rights analysis. Geneva: WHO; 2007.Google Scholar
  100. Molyneux DH. Neglected tropical diseases: now more than just ‘other diseases’ – the post-2015 agenda. Int Health. 2014;6(3):172–80.PubMedView ArticleGoogle Scholar
  101. World Health Organization Regional Office for Africa (WHO/AFRO). Regional strategy on neglected tropical diseases in the WHO African region: 2014–2020. Brazzaville: WHO/AFRO; 2013.Google Scholar
  102. Seddoh A, Onyeze A, Gyapong JO, Holt J, Bundy D. Towards an investment case for neglected tropical diseases - including new analysis of the cost of intervening against preventable NTDs in sub-Saharan Africa. Lancet commission on investing in health working paper. London: Lancet; 2013.Google Scholar
  103. Uniting to Combat NTDs. London declaration on neglected tropical diseases. Ending the neglect and reaching 2020 goals. London: Uniting to Combat NTDs; 2012.Google Scholar
  104. WHO. Global Health estimates 2015: DALYs by cause, age, sex, by country and by region, 2000–2015. Geneva: WHO; 2016.Google Scholar
  105. WHO. Water, sanitation and hygiene for accelerating and sustaining progress on neglected tropical diseases: a global strategy 2015–2020. Geneva: WHO; 2015.Google Scholar
  106. WHO/AFRO. Regional strategic plan for neglected tropical diseases in the African region 2014–2020. Brazzaville: WHO/AFRO; 2013.Google Scholar
  107. WHO. Accelerating work to overcome the global impact of neglected tropical diseases: a roadmap for implementation. Geneva: WHO; 2012.Google Scholar
  108. WHO. Global plan to combat neglected tropical diseases 2008–2015. Geneva: WHO; 2007.Google Scholar
  109. WHO/AFRO. Framework for the establishment of the expanded special project for elimination of neglected tropical diseases. Brazzaville: WHO/AFRO; 2015.Google Scholar
  110. African Union. Decision on the report of the sixth session of the conference of African union ministers of health and report of the fifth meeting of the African task force on food and nutrition development. The executive council decision EX.CL/Dec.795(XXIV). Addis Ababa, Ethiopia. Addis Ababa: AU; 2014.Google Scholar
  111. WHO. Neglected tropical diseases. Sixty-sixth world health assembly resolution WHA66.12. Geneva: WHO; 2013.Google Scholar
  112. WHO/AFRO. Regional strategy on neglected tropical diseases in the WHO African region. Sixty-third Regional Committee for Africa Resolution AFR/RC63/R6. Brazzaville: WHO/AFRO; 2013.Google Scholar
  113. Murray CJL, Lopez AD. The global burden of disease in 1990: final results and their sensitivity to alternative epidemiological perspectives, discount rates, age-weights and disability weights. In: Murray CJL, Lopez AD, editors. The global burden of disease. Geneva: WHO; 1996.Google Scholar
  114. Kirigia JM. The economics of Schistosomiasis interventions: a case study of the Mwea irrigation scheme in Kenya. Doctor of philosophy thesis. York: University of York; 1994.Google Scholar
  115. World Bank. World development report, 1993: investing in health. New York: Oxford University Press; 1993.View ArticleGoogle Scholar
  116. The Ghana Health Assessment Team. A quantitative method of assessing the health impact of different diseases in less developed countries. Int J Epidemiol. 1981;10:73–80.View ArticleGoogle Scholar
  117. Stiglitz JE, Sen A, Fitoussi J-P. Report of the commission on the measurement of economic performance and social progress. Paris: The Commission on the Measurement of Economic Performance and Social Progress; 2009.Google Scholar
  118. Nancy F. The invisible heart: economics and family values. New York: New Press; 2001.Google Scholar
  119. Nancy F. Holding hands at midnight: the paradox of caring labour. Fem Econ. 1995;1(1):73–92.View ArticleGoogle Scholar
  120. Luisella GC. Economic valuations of unpaid household work: Africa, Asia, Latin America and Oceania. In: women, work and development. Geneva: International Labour Organization; 1987.Google Scholar
  121. Hirway I. Unpaid work and the economy: linkages and their implications. J Labor Econ. 2015;58(1):1–21.View ArticleGoogle Scholar
  122. Saha S, Gerdtham UG. Cost of illness studies on reproductive, maternal, newborn, and child health: a systematic literature review. Health Econ Rev. 2013;3:24.PubMedPubMed CentralView ArticleGoogle Scholar
  123. Weiss MG. Stigma and the social burden of neglected tropical diseases. PLoS Negl Trop Dis. 2008;2(5):e237.PubMedPubMed CentralView ArticleGoogle Scholar
  124. Wiseman V, Mooney G. Burden of illness estimates for priority setting: a debate revisited. Health Policy. 1998;43(3):243–51.PubMedView ArticleGoogle Scholar
  125. Shiell A, Gerard K, Donaldson C. Cost of illness studies: an aid to decision-making? Health Policy. 1987;8(3):317–23.View ArticleGoogle Scholar
  126. Rispel LC, de Jager P, Fonn S. Exploring corruption in the south African health sector. Health Policy Plan. 2016;31(2):239–49.PubMedView ArticleGoogle Scholar
  127. Mostert S, Njuguna F, Olbara G, Sindano S, Sitaresmi MN, et al. Corruption in health-care systems and its effect on cancer care in Africa. Lancet Oncol. 2015;16(8):e394–404.PubMedView ArticleGoogle Scholar
  128. World Bank. Africa development indicators 2010: silent and lethal, how quiet corruption undermines Africa’s development efforts. Washington, D.C.: The World Bank; 2010.View ArticleGoogle Scholar
  129. Transparency International. Global corruption report 2006: corruption and health. London: Pluto Press; 2006.Google Scholar
  130. Kirigia JM. The essence of leadership in health development. Afr J Health Sci. 2008;15(1–2):1–3.Google Scholar
  131. Uneke CJ, Ezoeha AE, Ndukwe CD. Enhancing leadership and governance competencies to strengthen health systems in Nigeria: assessment of organizational human resource development. Healthc Policy. 2012;79(3):73–84.Google Scholar
  132. Kirigia JM, Kirigia DG. The essence of governance in health development. Int Arch Med. 2011;4:11.PubMedPubMed CentralView ArticleGoogle Scholar
  133. OECD. The Paris declaration on aid effectiveness and the Accra agenda for action. Paris: OECD; 2008.Google Scholar
  134. WHO. Everybody business: strengthening health systems to improve health outcomes: WHO’s framework for action. Geneva: WHO; 2007.Google Scholar
  135. African Union & WHO. Commitment on accountability mechanism to assess the implementation of commitments made by African ministers of health (AUC-WHO/COM.6/2014). First meeting of African ministers of health jointly convened by the AUC and WHO Luanda, Angola, 16–17 April, 2014. Addis Ababa: AU; 2014.Google Scholar
  136. Kirigia JM, Diarra-Nama AJ. Can countries of the WHO African region wean themselves off donor funding for health? Bull World Health Organ. 2008;86:889–95.PubMedPubMed CentralView ArticleGoogle Scholar


© The Author(s). 2018